PMCID	SUBJECT_SCOPE_ID	S_START	S_END	SUBJECT_SCOPE	CONCEPT	IGNORANCE TYPE	C_START	C_END	CONCEPT_MENTION_ID
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	pregnancy	GO_BP	[42]	[51]	PMC1974834_T79
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial	UBERON	[85]	[96]	PMC1974834_T277
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial activation	GO_BP	[85]	[107]	PMC1974834_T80
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	cord	UBERON	[228]	[232]	PMC1974834_T278
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	blood	UBERON	[233]	[238]	PMC1974834_T279
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial	UBERON	[280]	[291]	PMC1974834_T280
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial cell	CL	[280]	[296]	PMC1974834_T76
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	endothelial cell activation	GO_BP	[280]	[307]	PMC1974834_T81
PMC1974834	PMC1974834_0	[0]	[338]	['Effects of an antiatherogenic diet during pregnancy on markers of maternal and fetal endothelial activation and inflammation: the CARRDIP study\n\nAbstract\n\nObjective\nTo study the effect of an antiatherogenic diet on maternal and cord blood concentrations of systemic biomarkers of endothelial cell activation, haemostasis and inflammation.']	haemostasis	GO_BP	[309]	[320]	PMC1974834_T82
PMC1974834	PMC1974834_2	[401]	[491]	['Setting\nObstetric outpatient clinic and maternity unit of a university hospital in Norway.']	Obstetric	UBERON	[409]	[418]	PMC1974834_T281
PMC1974834	PMC1974834_3	[493]	[624]	['Population\nNonsmoking pregnant women aged 21–38 years carrying a single fetus and with no previous pregnancy-related complications.']	pregnant	GO_BP	[515]	[523]	PMC1974834_T83
PMC1974834	PMC1974834_3	[493]	[624]	['Population\nNonsmoking pregnant women aged 21–38 years carrying a single fetus and with no previous pregnancy-related complications.']	pregnancy	GO_BP	[592]	[601]	PMC1974834_T84
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	saturated	CHEBI	[725]	[734]	PMC1974834_T0
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	cholesterol	CHEBI	[743]	[754]	PMC1974834_T1
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	gestational	GO_BP	[760]	[771]	PMC1974834_T85
PMC1974834	PMC1974834_4	[626]	[792]	['Methods\nSubjects ( n = 290) were randomised to continue their usual diet or to adopt a diet low in saturated fat and cholesterol from gestational week 17–20 to birth.']	birth	GO_BP	[786]	[791]	PMC1974834_T86
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	molecules	CHEBI	[828]	[837]	PMC1974834_T2
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	high-sensitivity	PR	[839]	[855]	PMC1974834_T206
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	C-reactive protein	PR	[856]	[874]	PMC1974834_T207
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	CRP	PR	[876]	[879]	PMC1974834_T208
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	haemostatic	GO_BP	[885]	[896]	PMC1974834_T87
PMC1974834	PMC1974834_5	[793]	[989]	['Soluble forms of cellular adhesion molecules, high-sensitivity C-reactive protein (CRP) and haemostatic markers were measured at 17–20 weeks of gestation (baseline) and subsequently up to week 36.']	gestation	GO_BP	[937]	[946]	PMC1974834_T88
PMC1974834	PMC1974834_6	[990]	[1050]	['All the above, except CRP, were also measured in cord blood.']	cord	UBERON	[1039]	[1043]	PMC1974834_T282
PMC1974834	PMC1974834_6	[990]	[1050]	['All the above, except CRP, were also measured in cord blood.']	blood	UBERON	[1044]	[1049]	PMC1974834_T283
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	cord	UBERON	[1412]	[1416]	PMC1974834_T284
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	blood	UBERON	[1417]	[1422]	PMC1974834_T285
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	tissue	UBERON	[1423]	[1429]	PMC1974834_T286
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	plasminogen	CHEBI	[1430]	[1441]	PMC1974834_T3
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	plasminogen activator antigen	PR	[1430]	[1459]	PMC1974834_T209
PMC1974834	PMC1974834_9	[1275]	[1606]	['None of the maternal or fetal biomarkers were influenced by the intervention ( P> 0.05) except for a tendency to lower concentrations of cord blood tissue plasminogen activator antigen in the intervention group compared with the control group, median (interquartile range) 5.4 ng/ml (3.1–7.7) versus 5.8 ng/ml (3.5–11.8), P = 0.05.']	antigen	CHEBI	[1452]	[1459]	PMC1974834_T4
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	antiatherogenic	CHEBI	[1622]	[1637]	PMC1974834_T5
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	pregnancy	GO_BP	[1646]	[1655]	PMC1974834_T89
PMC1974834	PMC1974834_10	[1608]	[1769]	['Conclusion\nAn antiatherogenic diet in pregnancy did not significantly influence maternal or fetal blood concentrations of a range of biomarkers for inflammation.']	blood	UBERON	[1706]	[1711]	PMC1974834_T287
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	cholesterol	CHEBI	[1813]	[1824]	PMC1974834_T6
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	lipid	CHEBI	[1851]	[1856]	PMC1974834_T7
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	preterm	GO_BP	[1869]	[1876]	PMC1974834_T90
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	delivery	GO_BP	[1877]	[1885]	PMC1974834_T91
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	gestation	GO_BP	[1909]	[1918]	PMC1974834_T92
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	responses	GO_BP	[1980]	[1989]	PMC1974834_T93
PMC1974834	PMC1974834_11	[1770]	[2003]	['Thus, the previously reported effects of a cholesterol-lowering diet on maternal lipid profile and preterm delivery (<37 complete weeks of gestation) do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP	[1993]	[2002]	PMC1974834_T94
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP	[2035]	[2044]	PMC1974834_T95
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP	[2097]	[2106]	PMC1974834_T96
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	birthweight	GO_BP	[2112]	[2123]	PMC1974834_T97
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	preterm	GO_BP	[2128]	[2135]	PMC1974834_T98
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	delivery	GO_BP	[2136]	[2144]	PMC1974834_T99
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	coronary heart	UBERON	[2187]	[2201]	PMC1974834_T288
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	life	UBERON	[2219]	[2223]	PMC1974834_T289
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	uteroplacental circulation	UBERON	[2255]	[2281]	PMC1974834_T290
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	preterm	GO_BP	[2303]	[2310]	PMC1974834_T100
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	delivery	GO_BP	[2311]	[2319]	PMC1974834_T101
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP	[2374]	[2383]	PMC1974834_T102
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cardiovascular	UBERON	[2426]	[2440]	PMC1974834_T291
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	life	UBERON	[2455]	[2459]	PMC1974834_T292
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	Cardiovascular	UBERON	[2567]	[2581]	PMC1974834_T293
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	Risk Reduction ... in	GO_BP	[2582, 2602]	[2596, 2604]	PMC1974834_T103
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	Pregnancy	GO_BP	[2605]	[2614]	PMC1974834_T104
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cholesterol	CHEBI	[2702]	[2713]	PMC1974834_T8
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	antiatherogenic	CHEBI	[2733]	[2748]	PMC1974834_T9
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	antiatherogenic	GO_BP	[2733]	[2748]	PMC1974834_T105
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	cord	UBERON	[2842]	[2846]	PMC1974834_T294
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	lipid	CHEBI	[2860]	[2865]	PMC1974834_T10
PMC1974834	PMC1974834_12	[2005]	[2907]	['Introduction\nComplications of pregnancy, including pre-eclampsia, spontaneous loss of early pregnancy, low birthweight and preterm delivery, have been linked to the maternal risk of coronary heart disease in later life.1,2Pathological changes in the uteroplacental circulation in pre-eclampsia and preterm delivery share common features with atherosclerosis.3,4Adverse pregnancy outcomes are also related to the infant’s cardiovascular risk in later life.5,6Moreover, maternal hypercholesterolaemia is associated with fetal and childhood atherosclerosis.7,8\nThe Cardiovascular Risk Reduction Diet in Pregnancy (CARRDIP) trial was a randomised clinical trial designed to assess the effect of a low-cholesterol, low-saturated-fat antiatherogenic diet compared with the usual diet among nonsmoking white European healthy women on maternal, cord and neonatal lipid concentrations, and on pregnancy outcome.']	pregnancy	GO_BP	[2889]	[2898]	PMC1974834_T106
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	lipid	CHEBI	[2917]	[2922]	PMC1974834_T11
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	cord	UBERON	[2995]	[2999]	PMC1974834_T295
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	blood	UBERON	[3000]	[3005]	PMC1974834_T296
PMC1974834	PMC1974834_13	[2908]	[3060]	['Maternal lipid concentrations were reduced in the intervention arm of the trial, while cord blood and neonatal lipids did not differ between the groups.']	lipids	CHEBI	[3019]	[3025]	PMC1974834_T12
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	preterm	GO_BP	[3161]	[3168]	PMC1974834_T107
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	delivery	GO_BP	[3169]	[3177]	PMC1974834_T108
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	live birth	GO_BP	[3181]	[3191]	PMC1974834_T109
PMC1974834	PMC1974834_15	[3103]	[3259]	['However, there was a marked reduction in the incidence of preterm delivery (a live birth prior to 37 complete weeks of gestation) in the intervention group.']	gestation	GO_BP	[3222]	[3231]	PMC1974834_T110
PMC1974834	PMC1974834_16	[3260]	[3353]	['Gestational age was based on the ultrasound examination performed at week 17–18 of gestation.']	Gestational	GO_BP	[3260]	[3271]	PMC1974834_T111
PMC1974834	PMC1974834_16	[3260]	[3353]	['Gestational age was based on the ultrasound examination performed at week 17–18 of gestation.']	gestation	GO_BP	[3343]	[3352]	PMC1974834_T112
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP	[3446]	[3455]	PMC1974834_T113
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP	[3556]	[3565]	PMC1974834_T114
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	preterm	GO_BP	[3590]	[3597]	PMC1974834_T115
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	delivery	GO_BP	[3598]	[3606]	PMC1974834_T116
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	blood	UBERON	[3658]	[3663]	PMC1974834_T297
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecules	CHEBI	[3699]	[3708]	PMC1974834_T13
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	endothelial	UBERON	[3746]	[3757]	PMC1974834_T298
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	vascular adhesion molecule	PR	[3778]	[3804]	PMC1974834_T210
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	adhesion	GO_CC	[3787]	[3795]	PMC1974834_T198
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecule	CHEBI	[3796]	[3804]	PMC1974834_T14
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	VCAM-1	PR	[3806]	[3812]	PMC1974834_T211
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	1	GO_CC	[3811]	[3812]	PMC1974834_T199
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	intercellular adhesion molecule	PR	[3818]	[3849]	PMC1974834_T212
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	adhesion	GO_CC	[3832]	[3840]	PMC1974834_T200
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	molecule	CHEBI	[3841]	[3849]	PMC1974834_T15
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	ICAM	GO_CC	[3851]	[3855]	PMC1974834_T201
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	ICAM-1	PR	[3851]	[3857]	PMC1974834_T213
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	1	GO_CC	[3856]	[3857]	PMC1974834_T202
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	high-sensitivity	PR	[3949]	[3965]	PMC1974834_T214
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	C-reactive protein	PR	[3966]	[3984]	PMC1974834_T215
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	CRP	PR	[3986]	[3989]	PMC1974834_T216
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	cardiovascular	UBERON	[4034]	[4048]	PMC1974834_T299
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancies	GO_BP	[4214]	[4225]	PMC1974834_T117
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	prothrombotic	GO_BP	[4255]	[4268]	PMC1974834_T118
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	von Willebrand’s factor	PR	[4283]	[4306]	PMC1974834_T217
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	vWF	PR	[4308]	[4311]	PMC1974834_T218
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	fibrinolysis	GO_BP	[4337]	[4349]	PMC1974834_T119
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	plasminogen activator inhibitor type 1	PR	[4360]	[4398]	PMC1974834_T219
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	inhibitor	CHEBI	[4382]	[4391]	PMC1974834_T16
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI-1	PR	[4400]	[4405]	PMC1974834_T220
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI type 2	PR	[4417]	[4427]	PMC1974834_T221
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	PAI-2 antigen	PR	[4429]	[4442]	PMC1974834_T222
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	antigen	CHEBI	[4435]	[4442]	PMC1974834_T17
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tissue	UBERON	[4448]	[4454]	PMC1974834_T300
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tissue plasminogen activator antigen	PR	[4448]	[4484]	PMC1974834_T223
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	antigen	CHEBI	[4477]	[4484]	PMC1974834_T18
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	tPAag	PR	[4486]	[4491]	PMC1974834_T224
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	cardiovascular	UBERON	[4540]	[4554]	PMC1974834_T301
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP	[4613]	[4622]	PMC1974834_T120
PMC1974834	PMC1974834_17	[3354]	[4860]	['There were no differences between the intervention and control groups with respect to other pregnancy complications.9\nInflammatory mechanisms are involved in atherogenic processes as well as in several pregnancy complications including preterm delivery.10–13These mechanisms may be reflected in elevated blood concentrations of soluble adhesion molecules (sCAMs), markers of inflammation and endothelial activation, such as vascular adhesion molecule (VCAM-1) and intercellular adhesion molecule (ICAM-1), as has often been observed in pre-eclampsia.14–23On the other hand, the concentration of high-sensitivity C-reactive protein (CRP), though emerging as a potential marker for cardiovascular risk,24has not been shown to differ significantly in women who subsequently develop pre-eclampsia or fetal growth restriction compared with women with uncomplicated pregnancies.18,19Furthermore, markers of prothrombotic activity like von Willebrand’s factor (vWF) and markers of abnormal fibrinolysis including plasminogen activator inhibitor type 1 (PAI-1 activity), PAI type 2 (PAI-2 antigen) and tissue plasminogen activator antigen (tPAag) have been identified as independent markers of cardiovascular risk in several studies25–27and have also been related to pregnancy outcome.20–23\nSeveral studies in nonpregnant subjects have indicated that diet influences concentrations of sCAMs and other novel cardiovascular risk markers28–30but have not been studied in relation to dietary intervention in pregnancy.']	pregnancy	GO_BP	[4850]	[4859]	PMC1974834_T121
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	antiatherogenic	CHEBI	[4938]	[4953]	PMC1974834_T19
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	cord	UBERON	[4982]	[4986]	PMC1974834_T302
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	blood	UBERON	[4987]	[4992]	PMC1974834_T303
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	sCAMs	PR	[5012]	[5017]	PMC1974834_T225
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	thrombosis	GO_BP	[5030]	[5040]	PMC1974834_T122
PMC1974834	PMC1974834_18	[4861]	[5105]	['In this analysis of the CARRDIP population, we investigated the effect of an antiatherogenic diet on maternal and fetal (cord blood) concentrations of sCAMs, markers of thrombosis and fibrinolysis and on maternal levels of high-sensitivity CRP.']	fibrinolysis	GO_BP	[5045]	[5057]	PMC1974834_T123
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	pregnant	GO_BP	[5201]	[5209]	PMC1974834_T124
PMC1974834	PMC1974834_19	[5107]	[5407]	['Methods\nThe trial has been described in detail previously.9In brief, 290 healthy, nonsmoking, pregnant white European women aged 21–38 years, without a previous or current pregnancy complication and carrying a single healthy fetus, were randomised to follow their usual diet or the intervention diet.']	pregnancy	GO_BP	[5279]	[5288]	PMC1974834_T125
PMC1974834	PMC1974834_21	[5512]	[5774]	['who had no contact with the pregnant women (as described previously).9Sealed opaque envelopes consecutively numbered and containing the randomisation number and code (control or intervention) were given to the dietician responsible for giving the dietary advice.']	pregnant	GO_BP	[5540]	[5548]	PMC1974834_T126
PMC1974834	PMC1974834_21	[5512]	[5774]	['who had no contact with the pregnant women (as described previously).9Sealed opaque envelopes consecutively numbered and containing the randomisation number and code (control or intervention) were given to the dietician responsible for giving the dietary advice.']	opaque	NCBITAXON	[5589]	[5595]	PMC1974834_T205
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	cholesterol	CHEBI	[6032]	[6043]	PMC1974834_T20
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	fat	CHEBI	[6082]	[6085]	PMC1974834_T21
PMC1974834	PMC1974834_23	[5987]	[6158]	['The intervention diet aimed to limit dietary cholesterol and to reduce the intake of saturated fat by replacing saturated fat with monounsaturated and polyunsaturated fat.']	saturated fat	CHEBI	[6099]	[6112]	PMC1974834_T22
PMC1974834	PMC1974834_25	[6403]	[6548]	['Both the intervention and control groups followed the same schedule of blood sampling, physician and dietician visits and assessments (Figure 1).']	blood	UBERON	[6474]	[6479]	PMC1974834_T304
PMC1974834	PMC1974834_26	[6549]	[6631]	['Usual antenatal care was provided by the woman’s general physician and/or midwife.']	antenatal	GO_BP	[6555]	[6564]	PMC1974834_T127
PMC1974834	PMC1974834_31	[7115]	[7236]	['To assess dietary compliance, the weighed dietary intake was recorded on a predetermined day weekly throughout pregnancy.']	intake	GO_BP	[7165]	[7171]	PMC1974834_T128
PMC1974834	PMC1974834_31	[7115]	[7236]	['To assess dietary compliance, the weighed dietary intake was recorded on a predetermined day weekly throughout pregnancy.']	pregnancy	GO_BP	[7226]	[7235]	PMC1974834_T129
PMC1974834	PMC1974834_33	[7331]	[7390]	['All food and beverages consumed were described and weighed.']	food	CHEBI	[7335]	[7339]	PMC1974834_T23
PMC1974834	PMC1974834_33	[7331]	[7390]	['All food and beverages consumed were described and weighed.']	beverages	CHEBI	[7344]	[7353]	PMC1974834_T24
PMC1974834	PMC1974834_34	[7391]	[7645]	['The dietary records were entered into the database by certified personnel and scored using the software program Beregn developed by the Department of Nutrition, University of Oslo, and based on the Norwegian food table (1995; National Nutrition Council).']	food	CHEBI	[7599]	[7603]	PMC1974834_T25
PMC1974834	PMC1974834_35	[7646]	[7725]	['Foods or recipes that were not part of the programme were calculated and added.']	Foods	CHEBI	[7646]	[7651]	PMC1974834_T26
PMC1974834	PMC1974834_36	[7726]	[7788]	['Vitamin or iron supplements were not included in the analyses.']	Vitamin	CHEBI	[7726]	[7733]	PMC1974834_T27
PMC1974834	PMC1974834_37	[7790]	[7967]	['Laboratory methods\nBlood samples for measuring the risk markers (hereinafter referred to as biomarkers) were obtained at each visit after an overnight fast of at least 10 hours.']	Blood	UBERON	[7809]	[7814]	PMC1974834_T305
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	VCAM-1	PR	[7968]	[7974]	PMC1974834_T226
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	ICAM-1	PR	[7976]	[7982]	PMC1974834_T227
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	E-selectin	PR	[7987]	[7997]	PMC1974834_T228
PMC1974834	PMC1974834_38	[7968]	[8074]	['VCAM-1, ICAM-1 and E-selectin were measured at 17–20 weeks of gestation (baseline) and at weeks 30 and 36.']	gestation	GO_BP	[8030]	[8039]	PMC1974834_T130
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	PAI-1	PR	[8149]	[8154]	PMC1974834_T229
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	PAI-2	PR	[8156]	[8161]	PMC1974834_T230
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	tPAag	PR	[8163]	[8168]	PMC1974834_T231
PMC1974834	PMC1974834_40	[8149]	[8215]	['PAI-1, PAI-2, tPAag and vWF were measured at baseline and week 36.']	vWF	PR	[8173]	[8176]	PMC1974834_T232
PMC1974834	PMC1974834_41	[8216]	[8276]	['All the above, except CRP, were also measured in cord blood.']	cord	UBERON	[8265]	[8269]	PMC1974834_T306
PMC1974834	PMC1974834_41	[8216]	[8276]	['All the above, except CRP, were also measured in cord blood.']	blood	UBERON	[8270]	[8275]	PMC1974834_T307
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	Serum	UBERON	[8277]	[8282]	PMC1974834_T308
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	VCAM-1	PR	[8337]	[8343]	PMC1974834_T233
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	ICAM-1	GO_CC	[8345]	[8351]	PMC1974834_T203
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	ICAM-1	PR	[8345]	[8351]	PMC1974834_T234
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	E-selectin	PR	[8353]	[8363]	PMC1974834_T235
PMC1974834	PMC1974834_42	[8277]	[8372]	['Serum separated within 1 hour was used for determination of VCAM-1, ICAM-1, E-selectin and CRP.']	CRP	PR	[8368]	[8371]	PMC1974834_T236
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	Blood	UBERON	[8373]	[8378]	PMC1974834_T309
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	platelet	CL	[8402]	[8410]	PMC1974834_T77
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	plasma	UBERON	[8425]	[8431]	PMC1974834_T310
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	cord	UBERON	[8537]	[8541]	PMC1974834_T311
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	blood	UBERON	[8542]	[8547]	PMC1974834_T312
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	PAI-1	PR	[8578]	[8583]	PMC1974834_T237
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	PAI-2	PR	[8585]	[8590]	PMC1974834_T238
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	tPAag	PR	[8592]	[8597]	PMC1974834_T239
PMC1974834	PMC1974834_43	[8373]	[8606]	['Blood for the preparation of platelet-poor citrated plasma was collected, immediately placed on ice and centrifuged within 30 minutes (maternal samples) to 1 hour (cord blood samples) for determination of PAI-1, PAI-2, tPAag and vWF.']	vWF	PR	[8602]	[8605]	PMC1974834_T240
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	VCAM-1	PR	[8876]	[8882]	PMC1974834_T241
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	ICAM-1	PR	[8890]	[8896]	PMC1974834_T242
PMC1974834	PMC1974834_46	[8708]	[8925]	['sCAMs were analysed with kits provided by R&D Systems Europe, Abingdon, Oxon, UK, and the individual CAMs had the following coefficients of inter-assay variation (CV): VCAM-1, 5.2%; ICAM-1, 4.8%; and E-selectin, 5.3%.']	E-selectin	PR	[8908]	[8918]	PMC1974834_T243
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	haemostatic	GO_BP	[9165]	[9176]	PMC1974834_T131
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	PAI-1	PR	[9215]	[9220]	PMC1974834_T244
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	PAI-2	PR	[9266]	[9271]	PMC1974834_T245
PMC1974834	PMC1974834_49	[9111]	[9435]	['Commercial methods were also used for analyses of the haemostatic parameters as follows: Spectrolyse/pL PAI-1 (Biopool AB, Umeå, Sweden; CV 4.2%), Imubind PAI-2 (American Diagnostica Inc., Greenwich, CT, USA; CV 6.3%), TintElize tPAag (Biopool AB; CV 3.5%) and Asserachrom vWF (Stago Diagnostica, Asnieres, France; CV 8.0%).']	vWF	PR	[9384]	[9387]	PMC1974834_T246
PMC1974834	PMC1974834_50	[9436]	[9543]	['Fatty acid measurements were carried out in serum frozen immediately after venesection and stored at −70°C.']	Fatty acid	CHEBI	[9436]	[9446]	PMC1974834_T28
PMC1974834	PMC1974834_50	[9436]	[9543]	['Fatty acid measurements were carried out in serum frozen immediately after venesection and stored at −70°C.']	serum	UBERON	[9480]	[9485]	PMC1974834_T313
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	Serum	UBERON	[9631]	[9636]	PMC1974834_T314
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	fatty acid	CHEBI	[9643]	[9653]	PMC1974834_T29
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	gestational	GO_BP	[9698]	[9709]	PMC1974834_T132
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	lipids	CHEBI	[9732]	[9738]	PMC1974834_T30
PMC1974834	PMC1974834_52	[9631]	[9750]	['Serum total fatty acid profiles were determined at baseline and at gestational week 36 by extracting lipids from serum.']	serum	UBERON	[9744]	[9749]	PMC1974834_T315
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	transesterification	GO_BP	[9757]	[9776]	PMC1974834_T133
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	fatty acid	CHEBI	[9778]	[9788]	PMC1974834_T31
PMC1974834	PMC1974834_53	[9751]	[9866]	['After transesterification, fatty acid methyl esters were separated by means of capillary gas liquid chromatography.']	methyl esters	CHEBI	[9789]	[9802]	PMC1974834_T32
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acid	CHEBI	[9888]	[9898]	PMC1974834_T33
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acids	CHEBI	[9998]	[10009]	PMC1974834_T34
PMC1974834	PMC1974834_54	[9867]	[10066]	['The identity of each fatty acid peak was ascertained by comparison of the peak’s retention time relative to the retention times of fatty acids in a synthetic standard of known fatty acid composition.']	fatty acid	CHEBI	[10043]	[10053]	PMC1974834_T35
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acid	CHEBI	[10095]	[10105]	PMC1974834_T36
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acid	CHEBI	[10118]	[10128]	PMC1974834_T37
PMC1974834	PMC1974834_55	[10067]	[10249]	['The relative amount of each fatty acid (% of total fatty acid) was quantified by integration of the area under the peak and dividing the result by the total area for all fatty acids.']	fatty acids	CHEBI	[10237]	[10248]	PMC1974834_T38
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	antiatherogenic	CHEBI	[10453]	[10468]	PMC1974834_T39
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	endothelial	UBERON	[10507]	[10518]	PMC1974834_T316
PMC1974834	PMC1974834_57	[10396]	[10639]	['Statistical analyses\nThe assessment of the effects of an antiatherogenic diet on markers of maternal and fetal endothelial activation and inflammation was part of the secondary hypotheses of the CARRDIP study and part of the original protocol.']	endothelial activation	GO_BP	[10507]	[10529]	PMC1974834_T134
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI	[10763]	[10774]	PMC1974834_T40
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI	[10812]	[10823]	PMC1974834_T41
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI	[10985]	[10996]	PMC1974834_T42
PMC1974834	PMC1974834_58	[10640]	[11166]	['The power calculations were, however, based on our primary hypothesis concerning the expected difference in maternal total cholesterol levels at week 36 and neonatal total cholesterol levels in the intervention versus the control groups.9In brief, a sample size of 130 women in each group was required to detect a 5% reduction in maternal total cholesterol and a change of 15% (about 0.22 mmol/l) in neonatal total cholesterol levels between the two groups, ( α = 0.05; β = 0.20) in the intervention versus the control groups.']	cholesterol	CHEBI	[11055]	[11066]	PMC1974834_T43
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	pregnancy	GO_BP	[11271]	[11280]	PMC1974834_T135
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	Birth	GO_BP	[11325]	[11330]	PMC1974834_T136
PMC1974834	PMC1974834_60	[11238]	[11483]	['With an expected rate of adverse pregnancy outcome of 25% (data based on the Norwegian Birth Register), this number of participants had about 65% power with α set at 0.05 to find a 50% increase in the occurrence of any adverse pregnancy outcome.']	pregnancy	GO_BP	[11465]	[11474]	PMC1974834_T137
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP	[11503]	[11509]	PMC1974834_T138
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	macronutrients	CHEBI	[11513]	[11527]	PMC1974834_T44
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	food	CHEBI	[11532]	[11536]	PMC1974834_T45
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	pregnancy	GO_BP	[11551]	[11560]	PMC1974834_T139
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP	[11590]	[11596]	PMC1974834_T140
PMC1974834	PMC1974834_61	[11484]	[11661]	['Dietary energy and intake of macronutrients and food stuffs during pregnancy were expressed as mean daily intake, based on weighed recordings of intake from baseline to week 36.']	intake	GO_BP	[11629]	[11635]	PMC1974834_T141
PMC1974834	PMC1974834_64	[11873]	[11988]	['The tPAag concentrations in cord blood did not follow a normal distribution; hence, a Mann–Whitney U test was used.']	tPAag	PR	[11877]	[11882]	PMC1974834_T247
PMC1974834	PMC1974834_64	[11873]	[11988]	['The tPAag concentrations in cord blood did not follow a normal distribution; hence, a Mann–Whitney U test was used.']	cord	UBERON	[11901]	[11905]	PMC1974834_T317
PMC1974834	PMC1974834_64	[11873]	[11988]	['The tPAag concentrations in cord blood did not follow a normal distribution; hence, a Mann–Whitney U test was used.']	blood	UBERON	[11906]	[11911]	PMC1974834_T318
PMC1974834	PMC1974834_65	[11989]	[12153]	['However, due to the numerical differences shown in the percentiles (Table 4), an additional analysis based on the lognormal transformation of tPAag was carried out.']	tPAag	PR	[12131]	[12136]	PMC1974834_T248
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	endothelial	UBERON	[12274]	[12285]	PMC1974834_T319
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	endothelial activation	GO_BP	[12274]	[12296]	PMC1974834_T142
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	prothrombotic	GO_BP	[12301]	[12314]	PMC1974834_T143
PMC1974834	PMC1974834_67	[12214]	[12379]	['Caption (TABLE-WRAP): TABLE 4\n\nConcentrations of markers of endothelial activation and prothrombotic activity in cord blood in the control and intervention groupsNo.']	cord blood	UBERON	[12327]	[12337]	PMC1974834_T320
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	VCAM-1	PR	[12428]	[12434]	PMC1974834_T249
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	4ICAM-1	PR	[12479]	[12486]	PMC1974834_T250
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	3PAI-1	PR	[12682]	[12688]	PMC1974834_T251
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	6PAI-2	PR	[12740]	[12746]	PMC1974834_T252
PMC1974834	PMC1974834_68	[12380]	[12846]	['control/interventionControlIntervention P value*VCAM-1 (ng/ml)120/119813 (695, 970)836 (715, 993)0.4ICAM-1 (ng/ml)120/119149 (130, 167)148 (128, 174)0.7E-selectin (ng/ml)120/118150 (96.7, 189)159 (123, 201)0.08tPAag (ng/ml)119/1175.8 (3.5, 11.8)5.4 (3.1, 7.7)0.2vWF (%)107/10491 (66, 135)82 (54, 120)0.3PAI-1 activity (u/ml)118/1159.3 (4.6, 17.8)10.3 (5, 19)0.6PAI-2 antigen (ng/ml)119/1143.4 (1.1, 9.4)3.7 (1.9, 6.7)0.6\nValues shown are median (25, 75 percentiles).']	antigen	CHEBI	[12747]	[12754]	PMC1974834_T46
PMC1974834	PMC1974834_79	[14056]	[14610]	['No differences in baseline characteristics or dietary variables between the groups were observed before randomisation.9\n\nCaption (TABLE-WRAP): TABLE 1\n\nCharacteristics of participants at baselineCharacteristicControlIntervention P -valueNo.149141Age (years)29.8 (3.4)29.6 (3.7)0.7Nulliparous (%)65.170.90.3Gestational age at entry (week)19 (1.1)19 (1.1)0.919 (5.4)*19 (4.9)*BMI (kg/m2)24.3 (2.7)24.3 (2.9)0.9BMI (%) >25 (kg/m2)32.936.20.6Systolic blood pressure (mmHg)105 (10)106 (9)0.9Diastolic blood pressure (mmHg)65 (8)64 (8)0.4\nValues are mean (SD).']	blood	UBERON	[14503]	[14508]	PMC1974834_T321
PMC1974834	PMC1974834_79	[14056]	[14610]	['No differences in baseline characteristics or dietary variables between the groups were observed before randomisation.9\n\nCaption (TABLE-WRAP): TABLE 1\n\nCharacteristics of participants at baselineCharacteristicControlIntervention P -valueNo.149141Age (years)29.8 (3.4)29.6 (3.7)0.7Nulliparous (%)65.170.90.3Gestational age at entry (week)19 (1.1)19 (1.1)0.919 (5.4)*19 (4.9)*BMI (kg/m2)24.3 (2.7)24.3 (2.9)0.9BMI (%) >25 (kg/m2)32.936.20.6Systolic blood pressure (mmHg)105 (10)106 (9)0.9Diastolic blood pressure (mmHg)65 (8)64 (8)0.4\nValues are mean (SD).']	blood	UBERON	[14552]	[14557]	PMC1974834_T322
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	gestation	GO_BP	[14706]	[14715]	PMC1974834_T144
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	saturated fat	CHEBI	[14841]	[14854]	PMC1974834_T47
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	cholesterol	CHEBI	[14867]	[14878]	PMC1974834_T48
PMC1974834	PMC1974834_81	[14628]	[15070]	['Dietary adherence\nBased on dietary records of weighed intake from baseline to gestation week 36, the intervention group consumed less energy and total fat than the control group.9This was due to a lower intake of saturated fat and dietary cholesterol.9Compared with the control group, the intervention group significantly reduced their intake of fatty milk and meat products and significantly increased their intake of fish and fish products.']	intake	GO_BP	[15037]	[15043]	PMC1974834_T145
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	intake	GO_BP	[15084]	[15090]	PMC1974834_T146
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fatty fish	CHEBI	[15094]	[15104]	PMC1974834_T49
PMC1974834	PMC1974834_82	[15071]	[15245]	['Mean dietary intake of fatty fish and fish products during the study period was also significantly higher in the intervention group compared with the control group (Table 2).']	fish	CHEBI	[15109]	[15113]	PMC1974834_T50
PMC1974834	PMC1974834_84	[15362]	[15527]	['Moreover, the consumption of nuts, olives, seeds, fruits and vegetables was significantly higher in the intervention group compared with the control group (Table 2).']	consumption	GO_BP	[15376]	[15387]	PMC1974834_T147
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	intake	GO_BP	[15584]	[15590]	PMC1974834_T148
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	food	CHEBI	[15604]	[15608]	PMC1974834_T51
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Carbohydrates	CHEBI	[15851]	[15864]	PMC1974834_T52
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	milk	UBERON	[15953]	[15957]	PMC1974834_T323
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	milk	UBERON	[16003]	[16007]	PMC1974834_T324
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	Butter	CHEBI	[16298]	[16304]	PMC1974834_T53
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	margarines	CHEBI	[16344]	[16354]	PMC1974834_T54
PMC1974834	PMC1974834_85	[15529]	[16759]	['Caption (TABLE-WRAP): TABLE 2\n\nMean (SD) daily dietary intake from weighed food records during the study periodControl diet ( n = 141)Intervention diet ( n = 127) P value Total energy (kcal/day) 2189 (335)2031 (348)<0.001 Total fat (% of energy) 32.3 (3.4)30.0 (4.1)<0.001 Protein (% of energy) 14.7 (1.5)15.6 (1.6)<0.001 Carbohydrates (% of energy) 52.3 (3.7)53.7 (4.3)0.004Sugar (% energy)11.6 (4)9.1 (4.3)<0.001 Milk and milk products (g/day) 457 (172)415 (165)0.05Fatty milk (g/day)27 (40)14.2 (18.1)<0.001Cheese (g/day)37.1 (16.2)33.2 (17)0.07 Meat and meat products (g/day) 91.5 (28.9)75.2 (27.8)<0.001 Fatty minced meat (g/day) 7.5 (9)3.6 (6.1)<0.001 Fish and fish products (g/day) 48.6 (27.1)61.8 (24.5)<0.001Fatty (fish and products)16.0 (14.6)25.2 (16)<0.001 Butter (g/day) 3.8 (4.7)0.97 (2.1)<0.001 Hard margarines (g/day) 1.0 (1.4)0.4 (1.0)<0.001 Soft margarines (g/day) 16.6 (8.1)16.1 (9.4)0.7Rapeseed-based margarine0.97 (2.3)6.2 (5.1)<0.001 Oils (g/day) 3.6 (5.1)8 (4.8)<0.001Olive oil1.7 (2.5)6.8 (4.5)<0.001Rapeseed oil0.3 (1.0)1.4 (1.8)<0.001 Nuts, olives and seeds (g/day) 3.7 (5.1)7.6 (7.5)<0.001 Vegetables (g/day) 139 (57.5)165 (66.5)0.001 Fruits (g/day) 407 (147)471 (171)0.002\nT-test for group differences.']	margarines	CHEBI	[16393]	[16403]	PMC1974834_T55
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	myristic acid	CHEBI	[16776]	[16789]	PMC1974834_T56
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	serum	UBERON	[16807]	[16812]	PMC1974834_T325
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	fatty acids	CHEBI	[16819]	[16830]	PMC1974834_T57
PMC1974834	PMC1974834_86	[16760]	[17061]	['The increase in myristic acid (C14:0) level in serum total fatty acids from baseline to week 36 was significantly lower in the intervention group compared with the control group, while eicosapentaenic acid (C20:5) levels tended to increase more in the intervention than in the control group (Table 3).']	eicosapentaenic acid	CHEBI	[16945]	[16965]	PMC1974834_T58
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	Fatty acid	CHEBI	[17094]	[17104]	PMC1974834_T59
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	serum	UBERON	[17129]	[17134]	PMC1974834_T326
PMC1974834	PMC1974834_87	[17063]	[17982]	['Caption (TABLE-WRAP): TABLE 3\n\nFatty acid composition (% of total serum fatty acids) at baseline and week 36Control ( n = 129)Intervention ( n = 125) P *BaselineWeek 36BaselineWeek 36C14:00 (0, 0)0 (0, 0.7)0 (0, 0)0 (0, 0.6)0.02C14:0**0.15 (0.33)0.35 (0.39)0.18 (0.33)0.28 (0.38)C16:026.5 (25.3, 28.1)29.5 (28.1, 31.4)26.5 (25.2, 27.9)29.3 (27.5, 31.0)0.4C18:07.5 (6.7, 8.1)7.2 (6.3, 7.8)7.6 (6.9, 8.1)7.0 (6.5, 7.6)0.1C18:121.1 (19.6, 22.5)21.8 (20.3, 24.0)20.7 (19.2, 22.2)22.2 (20.5, 24.2)0.3C18:227.6 (25.4, 29.9)25.6 (24.3, 28.6)27.7 (25.3, 30.6)26.3 (24.4, 28.6)0.7C18:30.7 (0, 0.8)0.7 (0.5, 0.8)0.7 (0, 0.8)0.7 (0, 0.8)0.8C20:47.0 (6.1, 7.8)5.9 (5.2, 6.7)6.9 (6.2, 7.9)5.9 (5.1, 6.7)0.1C20:50.9 (0.4, 1.4)0.6 (0, 1.0)1.0 (0, 1.5)0.7 (0,1.4)0.06C22:67.6 (5.9, 9.6)6.5 (4.7, 8.5)7.6 (5.9, 9.4)6.7 (5.0, 8.5)0.7\nData are shown as median (25,75 percentiles), except for C14:0 where\nmean (SD) values are supplemented.']	fatty acids	CHEBI	[17135]	[17146]	PMC1974834_T60
PMC1974834	PMC1974834_89	[18045]	[18440]	['Maternal biomarkers and the dietary intervention\nOver the duration of the study period (between baseline and week 36), there was a significant increase in the concentrations of sCAMs and the haemostatic markers both within the intervention and control groups analysed separately (Figures 2and3; P< 0.01 for all variables) and within the entire cohort (data not shown; P< 0.01 for all variables).']	haemostatic	GO_BP	[18236]	[18247]	PMC1974834_T149
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	sCAMs	PR	[18643]	[18648]	PMC1974834_T253
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	haemostatic	GO_BP	[18662]	[18673]	PMC1974834_T150
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	gestation	GO_BP	[18859]	[18868]	PMC1974834_T151
PMC1974834	PMC1974834_91	[18625]	[18913]	['Concentrations of sCAMs, CRP and the haemostatic markers did not differ between the control and intervention groups (Figures 2and3, P values are shown with each boxplot and refer to group differences for changes in those markers from gestation week 17–20 [baseline] to gestation week 36).']	gestation	GO_BP	[18894]	[18903]	PMC1974834_T152
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP	[19363]	[19372]	PMC1974834_T153
PMC1974834	PMC1974834_94	[19284]	[19416]	['P values refer to group differences expressed as changes in those markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP	[19398]	[19407]	PMC1974834_T154
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	haemostatic	GO_BP	[19481]	[19492]	PMC1974834_T155
PMC1974834	PMC1974834_95	[19418]	[19600]	['Caption (FIG): FIGURE 3\n\nBoxplot for the concentrations of the haemostatic markers (markers of prothrombotic activity) during the study period in the control and intervention groups.']	prothrombotic	GO_BP	[19513]	[19526]	PMC1974834_T156
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	haemostatic	GO_BP	[19665]	[19676]	PMC1974834_T157
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP	[19690]	[19699]	PMC1974834_T158
PMC1974834	PMC1974834_96	[19601]	[19743]	['P values refer to group differences expressed as changes in the haemostatic markers from gestation week 17–20 (baseline) to gestation week 36.']	gestation	GO_BP	[19725]	[19734]	PMC1974834_T159
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	cord	UBERON	[19759]	[19763]	PMC1974834_T327
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	blood	UBERON	[19764]	[19769]	PMC1974834_T328
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	sCAMs	PR	[19794]	[19799]	PMC1974834_T254
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	haemostatic	GO_BP	[19804]	[19815]	PMC1974834_T160
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	cord	UBERON	[19827]	[19831]	PMC1974834_T329
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	blood	UBERON	[19832]	[19837]	PMC1974834_T330
PMC1974834	PMC1974834_97	[19745]	[20145]	['Biomarkers in cord blood\nConcentrations of fetal sCAMs and haemostatic markers in cord blood did not differ between the groups, with the exception of tPAag concentrations, which tended to be numerically lower in the intervention group compared with the control group (Table 4; a two-sample t test on lognormal-transformed values of tPAag gave a P value of 0.05 for the difference between the groups).']	tPAag	PR	[19895]	[19900]	PMC1974834_T255
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	pregnancies	GO_BP	[20259]	[20270]	PMC1974834_T161
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	antiatherogenic	CHEBI	[20297]	[20312]	PMC1974834_T61
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	haemostatic	GO_BP	[20363]	[20374]	PMC1974834_T162
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	PAI-1	PR	[20387]	[20392]	PMC1974834_T256
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	PAI-2	PR	[20394]	[20399]	PMC1974834_T257
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	tPAag	PR	[20401]	[20406]	PMC1974834_T258
PMC1974834	PMC1974834_98	[20147]	[20468]	['Discussion\nIn this randomised controlled trial (Figure 4) of healthy white European subjects carrying singleton pregnancies, we found no effect of an antiatherogenic diet on maternal concentrations of sCAMs, CRP and haemostatic parameters (PAI-1, PAI-2, tPAag and vWF) between the dietary intervention and control groups.']	vWF	PR	[20411]	[20414]	PMC1974834_T259
PMC1974834	PMC1974834_99	[20469]	[20661]	['Moreover, no differences were found between the groups in concentrations of the fetal blood variables measured other than a tendency to lower concentrations of tPAag in the intervention group.']	blood	UBERON	[20555]	[20560]	PMC1974834_T331
PMC1974834	PMC1974834_99	[20469]	[20661]	['Moreover, no differences were found between the groups in concentrations of the fetal blood variables measured other than a tendency to lower concentrations of tPAag in the intervention group.']	tPAag	PR	[20629]	[20634]	PMC1974834_T260
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	preterm	GO_BP	[20749]	[20756]	PMC1974834_T163
PMC1974834	PMC1974834_100	[20662]	[20840]	['Thus, the previously reported preventive effect of the current dietary intervention on preterm delivery is not likely to involve modification of systemic inflammatory biomarkers.']	delivery	GO_BP	[20757]	[20765]	PMC1974834_T164
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	endothelial	UBERON	[20952]	[20963]	PMC1974834_T332
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	endothelial activation	GO_BP	[20952]	[20974]	PMC1974834_T165
PMC1974834	PMC1974834_101	[20842]	[21068]	['Caption (FIG): FIGURE 4\n\nTrial profile.9\nTo our knowledge, the effect of a dietary intervention on markers of endothelial activation and inflammation has not been studied previously in women of fertile age or during pregnancy.']	pregnancy	GO_BP	[21058]	[21067]	PMC1974834_T166
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	serum	UBERON	[21223]	[21228]	PMC1974834_T333
PMC1974834	PMC1974834_102	[21069]	[21319]	['The reported significant differences in dietary saturated and unsaturated fat intakes between the groups are supported by the observed difference in some serum fatty acid levels (myristic, eicosapentaenic) between the intervention and control groups.']	fatty acid	CHEBI	[21229]	[21239]	PMC1974834_T62
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	ICAM	PR	[21476]	[21480]	PMC1974834_T261
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	tPAag	PR	[21485]	[21490]	PMC1974834_T262
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	antiatherogenic	CHEBI	[21580]	[21595]	PMC1974834_T63
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnancy	GO_BP	[21604]	[21613]	PMC1974834_T167
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	endothelial	UBERON	[21628]	[21639]	PMC1974834_T334
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	endothelial activation	GO_BP	[21628]	[21650]	PMC1974834_T168
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnant	GO_BP	[21755]	[21763]	PMC1974834_T169
PMC1974834	PMC1974834_103	[21320]	[21811]	['Dietary counselling, similar to the advice given to the intervention group in our study but which extended over a 3-year interval, has been shown to reduce ICAM and tPAag concentrations in a randomised trial of men aged 65–75 years.29\nThe lack of effect of an antiatherogenic diet in pregnancy on markers of endothelial activation and inflammation may be limited to the current study population, which consisted of healthy, nonsmoking pregnant women with no previous pregnancy complications.']	pregnancy	GO_BP	[21787]	[21796]	PMC1974834_T170
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	total	CHEBI	[21966]	[21971]	PMC1974834_T64
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	cholesterol	CHEBI	[21972]	[21983]	PMC1974834_T65
PMC1974834	PMC1974834_105	[21935]	[22145]	['reducing maternal and neonatal total cholesterol levels.9The major strength of the CARRDIP study, on the other hand, is that it is a randomised dietary intervention trial in pregnancy with a prospective design.']	pregnancy	GO_BP	[22109]	[22118]	PMC1974834_T171
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	intake	GO_BP	[22181]	[22187]	PMC1974834_T172
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	serum	UBERON	[22252]	[22257]	PMC1974834_T335
PMC1974834	PMC1974834_106	[22146]	[22277]	['In addition, the different dietary intake between the groups was verified through characterisation of the serum fatty acid profile.']	fatty acid	CHEBI	[22258]	[22268]	PMC1974834_T66
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	cholesterol	CHEBI	[22335]	[22346]	PMC1974834_T67
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	gestation	GO_BP	[22365]	[22374]	PMC1974834_T173
PMC1974834	PMC1974834_107	[22278]	[22534]	['Maternal concentrations of low-density lipoprotein (LDL) cholesterol increased through gestation as expected,9but the observed decrease in LDL cholesterol concentrations in the intervention arm9was not accompanied by lower CRP concentrations in this group.']	cholesterol	CHEBI	[22421]	[22432]	PMC1974834_T68
PMC1974834	PMC1974834_109	[22818]	[22914]	['We have not identified any previously published longitudinal studies of CRP levels in pregnancy.']	pregnancy	GO_BP	[22904]	[22913]	PMC1974834_T174
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	gestation	GO_BP	[22949]	[22958]	PMC1974834_T175
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	pregnancy	GO_BP	[22990]	[22999]	PMC1974834_T176
PMC1974834	PMC1974834_110	[22915]	[23245]	['CRP concentrations at 13 weeks of gestation are highly correlated with pre-pregnancy adiposity.31Our findings concerning the significant positive correlation between baseline CRP and baseline BMI in the entire cohort suggest that adiposity is a factor influencing the level of CRP in pregnancy, as seen in nonpregnant populations.']	pregnancy	GO_BP	[23199]	[23208]	PMC1974834_T177
PMC1974834	PMC1974834_111	[23246]	[23383]	['In normal pregnancy, concentrations of most clotting factors are reported to increase,32and our results agree with previous observations.']	pregnancy	GO_BP	[23256]	[23265]	PMC1974834_T178
PMC1974834	PMC1974834_111	[23246]	[23383]	['In normal pregnancy, concentrations of most clotting factors are reported to increase,32and our results agree with previous observations.']	clotting	GO_BP	[23290]	[23298]	PMC1974834_T179
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	Fibrinolytic	GO_BP	[23384]	[23396]	PMC1974834_T180
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tissue	UBERON	[23420]	[23426]	PMC1974834_T336
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tissue plasminogen activator	PR	[23420]	[23448]	PMC1974834_T263
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	plasminogen activator inhibitors	PR	[23505]	[23537]	PMC1974834_T264
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	inhibitors	CHEBI	[23527]	[23537]	PMC1974834_T69
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-1	PR	[23538]	[23543]	PMC1974834_T265
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-2	PR	[23548]	[23553]	PMC1974834_T266
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	tPAag	PR	[23599]	[23604]	PMC1974834_T267
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	vWF	PR	[23606]	[23609]	PMC1974834_T268
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-1	PR	[23611]	[23616]	PMC1974834_T269
PMC1974834	PMC1974834_112	[23384]	[23696]	['Fibrinolytic activity diminishes as tissue plasminogen activator activity decreases, probably due to the increase in the plasminogen activator inhibitors PAI-1 and PAI-2.32We observed increases in concentrations of tPAag, vWF, PAI-1 and PAI-2 from baseline to week 36 in both the control and intervention groups.']	PAI-2	PR	[23621]	[23626]	PMC1974834_T270
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	cholesterol	CHEBI	[23805]	[23816]	PMC1974834_T70
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	pregnancies	GO_BP	[23844]	[23855]	PMC1974834_T181
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	saturated fat9is	CHEBI	[23876]	[23892]	PMC1974834_T71
PMC1974834	PMC1974834_114	[23754]	[24022]	['This finding indicates that lowering total and LDL cholesterol concentrations in low-risk pregnancies by lowering dietary saturated fat9is not accompanied by changes in haemostatic variables, at least not within the range of LDL lowering achieved in the present study.']	haemostatic	GO_BP	[23923]	[23934]	PMC1974834_T182
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental unit	UBERON	[24091]	[24110]	PMC1974834_T337
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	preterm	GO_BP	[24208]	[24215]	PMC1974834_T183
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP	[24216]	[24224]	PMC1974834_T184
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental spiral arteries	UBERON	[24316]	[24346]	PMC1974834_T338
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	preterm	GO_BP	[24374]	[24381]	PMC1974834_T185
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP	[24382]	[24390]	PMC1974834_T186
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	lipid	CHEBI	[24462]	[24467]	PMC1974834_T72
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	ICAM-1	GO_CC	[24546]	[24552]	PMC1974834_T204
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	ICAM-1	PR	[24546]	[24552]	PMC1974834_T271
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	cervicovaginal fluid	UBERON	[24556]	[24576]	PMC1974834_T339
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	preterm	GO_BP	[24626]	[24633]	PMC1974834_T187
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	delivery	GO_BP	[24634]	[24642]	PMC1974834_T188
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	preterm	GO_BP	[24669]	[24676]	PMC1974834_T189
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	blood	UBERON	[24738]	[24743]	PMC1974834_T340
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	uteroplacental	UBERON	[24907]	[24921]	PMC1974834_T341
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	cervical	UBERON	[24925]	[24933]	PMC1974834_T342
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	leukocyte	CL	[24994]	[25003]	PMC1974834_T78
PMC1974834	PMC1974834_115	[24023]	[25028]	['Inflammatory processes have been shown to take place locally in the uteroplacental unit, especially in pre-eclampsia.33Such local inflammatory processes may also occur in some cases of preterm delivery, since it has been shown that failure of physiological transformation and atherosis of the uteroplacental spiral arteries are often seen in cases of preterm delivery and bear several similarities to atherosclerosis in general, including lipid deposition and inflammatory features.3,4Moreover, increased concentrations of ICAM-1 in cervicovaginal fluid have been considered as a potential predictor of preterm delivery in women with symptoms of preterm labour.34Although we did not find significant changes in the blood concentrations of the measured inflammatory markers, we cannot exclude the possibility that the dietary intervention somehow may have lead to changes in the local uteroplacental or cervical inflammatory response involving, for example, less enhanced leukocyte/endothelial interaction.']	endothelial	UBERON	[25004]	[25015]	PMC1974834_T343
PMC1974834	PMC1974834_116	[25029]	[25165]	['Whether lowering of maternal LDL cholesterol is directly involved in initiating a local anti-inflammatory response remains a hypothesis.']	cholesterol	CHEBI	[25062]	[25073]	PMC1974834_T73
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	tPAag	PR	[25332]	[25337]	PMC1974834_T272
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	cord blood	UBERON	[25341]	[25351]	PMC1974834_T344
PMC1974834	PMC1974834_117	[25166]	[25431]	['Another finding, which supports the notion of a possible local effect in the intervention group, is that we observed a tendency towards lower concentrations of fetal tPAag in cord blood of fetuses born to mothers in the intervention compared with the control group.']	born	GO_BP	[25363]	[25367]	PMC1974834_T190
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	cord	UBERON	[25450]	[25454]	PMC1974834_T345
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	blood	UBERON	[25455]	[25460]	PMC1974834_T346
PMC1974834	PMC1974834_118	[25432]	[25518]	['To our knowledge, cord blood tPAag concentrations are not described in the literature.']	tPAag	PR	[25461]	[25466]	PMC1974834_T273
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	tPAag	PR	[25519]	[25524]	PMC1974834_T274
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	coronary heart	UBERON	[25609]	[25623]	PMC1974834_T347
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	tPAag	PR	[25681]	[25686]	PMC1974834_T275
PMC1974834	PMC1974834_119	[25519]	[25765]	['tPAag is regarded a marker of atherosclerotic activity and to be an independent marker of coronary heart disease.25,35The effect of the diet on concentrations of tPAag in fetal blood is in accordance with the intervention study of Hjerkinn et al.']	blood	UBERON	[25696]	[25701]	PMC1974834_T348
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	tPAag	PR	[25916]	[25921]	PMC1974834_T276
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	cord	UBERON	[25925]	[25929]	PMC1974834_T349
PMC1974834	PMC1974834_120	[25766]	[25960]	['29However, we suggest that future studies attempting to assess a possible local effect of the intervention diet should include power calculations for tPAag in cord blood as a primary hypothesis.']	blood	UBERON	[25930]	[25935]	PMC1974834_T350
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	antiatherogenic	CHEBI	[26001]	[26016]	PMC1974834_T74
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	pregnancy	GO_BP	[26029]	[26038]	PMC1974834_T191
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	endothelial	UBERON	[26056]	[26067]	PMC1974834_T351
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	endothelial activation	GO_BP	[26056]	[26078]	PMC1974834_T192
PMC1974834	PMC1974834_121	[25961]	[26109]	['In conclusion, we found no effect of an antiatherogenic diet during pregnancy on biomarkers of endothelial activation, inflammation and haemostasis.']	haemostasis	GO_BP	[26097]	[26108]	PMC1974834_T193
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP	[26250]	[26259]	PMC1974834_T194
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	lipid	CHEBI	[26272]	[26277]	PMC1974834_T75
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	preterm	GO_BP	[26298]	[26305]	PMC1974834_T195
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	delivery	GO_BP	[26306]	[26314]	PMC1974834_T196
PMC1974834	PMC1974834_123	[26193]	[26398]	['Thus, the previously reported effects of the diet during pregnancy on maternal lipid profile and risk of preterm delivery do not seem to involve changes in the systemic inflammatory responses of pregnancy.']	pregnancy	GO_BP	[26388]	[26397]	PMC1974834_T197
PMC1974834	PMC1974834_124	[26400]	[26488]	['© RCOG 2007 BJOG An International Journal of Obstetrics and Gynaecology\n\nPubMed Central:']	Gynaecology	UBERON	[26460]	[26471]	PMC1974834_T352
